Mesoblast limited trading halt leaves it on the edge

Mesoblast limited (ASX:MSB) shares will be volatile when it returns to the ASX boards.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in regenerative medicine business Mesoblast limited (ASX: MSB) are locked in a trading halt this afternoon with the company set to announce "material corporate developments with respect to certain assets of the company".

Although the company is keeping its cards close to its chest for investors this looks to present two distinct possible outcomes. One good. One bad. The optimists will expect a partnership deal to be announced with a major pharmaceutical partner to help the company trial and commercialise its regenerative medicine products for either back pain or rheumatoid arthritis (RA).

The company is expecting the first phase III interim results for its back pain trials in Q4 2016 and any news that it has secured a partner in these trials is sure to be cheered by investors. While its RA program is also searching for a partner with trials currently in the Phase II stage. The company is expected to provide an update on the progress of its RA trial in Q3 2016.

It has also long been working with US pharmaceutical giant Teva on its regenerative medicine treatment for chronic heart failure (CHF) where trials are currently at an early Phase III stage.

However, the pessimists may expect that Teva has gotten cold feet over the potential of the program, with several analysts getting cold feet themselves after the company provided a disappointing quarterly update last month.

As a result even its cheerleader-in-chief and US IPO bookrunner JP Morgan downgraded its rating to neutral from buy, with other analysts questioning why another partner named Celgene had not invested further into Mesoblast.

In May I decided to dump a small holding in the business largely on valuation grounds and the disappointing quarterly update as it remains on a whopping valuation, with plenty of risk to the downside. If the news is related to Teva pulling back in its partnership I expect the share price will cop an almighty hiding when it resumes trade.

However, if the company does deliver positive partnership or trial data news in the next few days I will be left regretting that decision as the share price is likely to rocket.

Elsewhere in the biotech space liver cancer treatment specialist Sirtex Medical Limtied (ASX: SRX) has released revised guidance for dose sales growth in the region of 15%-17% over FY16. This is down on prior guidance of at least 19.8%, although its core US market is still expected to deliver growth in the region of 18%-20%. The stock is down 7.6% to $29.10 as investors react to the announcement.

Motley Fool contributor Tom Richardson owns shares of Sirtex Medical Limited. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »